Fibrates in the treatment of cardiovascular risk and atherogenic dyslipidaemia

Current Opinion in Cardiology

Volumn 24, Issue 4, 2009, Pages 372-379

  Wierzbicki, Anthony S ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Cardiovascular prevention; Creatinine; Diabetes; Fibrate; Homocysteine; Macrovascular disease; Metabolic syndrome; Microvascular disease; Niacin

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; BEZAFIBRATE; CLOFIBRATE; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PIOGLITAZONE; PLACEBO; CLOFIBRIC ACID; CREATININE; HOMOCYSTEINE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFECT; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; HEART INFARCTION; HUMAN; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; METABOLIC SYNDROME X; MICROANGIOPATHY; MORTALITY; MYOCARDIAL DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; STROKE; TREATMENT RESPONSE; CARDIOVASCULAR DISEASES; DRUG EFFECTS; DYSLIPIDEMIAS;

ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CLOFIBRIC ACID; CREATININE; DIABETES MELLITUS; DYSLIPIDEMIAS; HOMOCYSTEINE; HUMANS; METABOLIC SYNDROME X; NIACIN; HYPOLIPIDEMIC AGENTS;

EID: 67651149646     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e32832c0b3d     Document Type: Review

References (24)

1. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Executive summary of the third report of The National Cholesterol Education Program (NCEP). J Am Med Assoc 2001; 285:2486-2497.
2. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Atherosclerosis 2007; 194:1-45. (Pubitemid 47470068)
3. British Cardiac Society, British Hypertension Society, Diabetes UK, HEART UK. Primary Care Cardiovascular Society, The Stroke Association: JBS 2: the Joint British Societies' guidelines for prevention of cardiovascular disease in clinical practice. Heart 2005; 91(Suppl V):v1-v52.
4. Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES. Efficacy and safety of highdensity lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2005; 45:185-197. (Pubitemid 40094724)
5. Briel M, Ferreira-Gonzalez I, You JJ, et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. Br Med J 2009; 338:b92.
6. Schaefer EJ, Genest JJ Jr, Ordovas JM, et al. Familial lipoprotein disorders and premature coronary artery disease. Atherosclerosis 1994; 108 (Suppl):S41-S54. (Pubitemid 24303518)
7. Bruckert E, Hansel B. HDL-c is a powerful lipid predictor of cardiovascular diseases. Int J Clin Pract 2007; 61:1905-1913. (Pubitemid 47573086)
8. Bruckert E, Baccara-Dinet M, McCoy F, Chapman J. High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients. Curr Med Res Opin 2005; 21:1927-1934. (Pubitemid 41803102)
9. Austin MA. Triglyceride, small, dense low-density lipoprotein, and the atherogenic lipoprotein phenotype. Curr Atheroscler Rep 2000; 2:200-207.
10. Tan MH, Johns D, Glazer NB. Pioglitazone reduces atherogenic index of plasma in patients with type 2 diabetes. Clin Chem 2004; 50:1184-1188. (Pubitemid 38824226)
11. Wierzbicki AS. Low HDL-cholesterol: common and under-treated, but which drug to use? Int J Clin Pract 2006; 60:1149-1153.
12. Chapman MJ. Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis 2003; 171:1-13.
13. Hiukka A, Westerbacka J, Leinonen ES, et al. Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus. J Am Coll Cardiol 2008; 52:2190-2197.
14. Wierzbicki AS. FIELDS of dreams, fields of tears: a perspective on the fibrate trials. Int J Clin Pract 2006; 60:442-449.
15. Klosiewicz-Latoszek L, Szostak WB. Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia. Eur J Clin Pharmacol 1991; 40:33-41.
16. Elisaf M. Effects of fibrates on serum metabolic parameters. Curr Med Res Opin 2002; 18:269-276. (Pubitemid 35014543)
17. Muhlestein JB, May HT, Jensen JR, et al. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. J Am Coll Cardiol 2006; 48:396-401.
18. Watts GF, Ji J, Chan DC, et al. Relationships between changes in plasma lipid transfer proteins and apolipoprotein B-100 kinetics during fenofibrate treatment in the metabolic syndrome. Clin Sci (Lond) 2006; 111:193-199. (Pubitemid 44352192)
19. Rubenstrunk A, Hanf R, Hum DW, et al. Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta 2007; 1771:1065-1081. (Pubitemid 47208546)
20. A group of physicians of the Newcastle upon Tyne Region. Trial of clofibrate in the treatment of ischaemic heart disease. Five-year study by a group of physicians of the Newcastle upon Tyne region. Br Med J 1971; 4:767-775.
21. Research Committee of Scottish Society of Physicians. Ischaemic heart disease: a secondary prevention trial using clofibrate. Report by a research committee of the Scottish Society of Physicians. Br Med J 1971; 4:775-784.
22. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. J Am Med Assoc 1975; 231:360-381.
23. Committee of Principal Investigators. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators. Br Heart J 1978; 40:1069-1118.
24. Committee of Principal Investigators. WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Report of the Committee of Principal Investigators. Lancet 1984; 2:600-604.